Deals & business · first seen 12h ago, updated 12h ago
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
The new partnership follows Roche’s recent R&D expansion in Boston focused on development for cardiovascular, renal and metabolic diseases.
Summary from BioSpace - All News.
Coverage 1 article · 1 outlet
-
BioSpace - All NewsRoche inks up to $2B deal with Atavistik for new cardiometabolic drugs